𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study

✍ Scribed by Tanja Sikjaer; Lars Rejnmark; Lars Rolighed; Lene Heickendorff; Leif Mosekilde; the Hypoparathyroid Study Group


Publisher
American Society for Bone and Mineral Research
Year
2011
Tongue
English
Weight
229 KB
Volume
26
Category
Article
ISSN
0884-0431

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

In hypoparathyroidism, plasma parathyroid hormone (PTH) levels are inadequate to maintain plasma calcium concentration within the reference range. On conventional treatment with calcium supplements and active vitamin D analogues, bone turnover is abnormally low, and BMD is markedly increased. We aimed to study the effects of PTH‐replacement therapy (PTH‐RT) on calcium‐phosphate homeostasis and BMD. In a double‐blind design, we randomized 62 patients with hypoparathyroidism to daily treatment with PTH(1–84) 100 µg or similar placebo for 24 weeks as add‐on therapy to conventional treatment. Compared with placebo, patients on PTH(1–84) reduced their daily dose of calcium and active vitamin D significantly by 75% and 73%, respectively, without developing hypocalcemia. However, hypercalcemia occurred frequently during the downtitration of calcium and active vitamin D. Plasma phosphate and renal calcium and phosphate excretion did not change. Compared with placebo, PTH(1–84) treatment significantly increased plasma levels of bone‐specific alkaline phosphatase (+226% ± 36%), osteocalcin (+807% ± 186%), N‐terminal propeptide of procollagen 1 (P1NP; +1315% ± 330%), cross‐linked C‐telopeptide of type 1 collagen (CTX; +1209% ± 459%), and urinary cross‐linked N‐telopeptide of type 1 collagen (NTX; (+830% ± 165%), whereas BMD decreased at the hip (−1.59% ± 0.57%), lumbar spine (−1.76% ± 1.03%), and whole body (−1.26% ± 0.49%) but not at the forearm. In conclusion, the need for calcium and active vitamin D is reduced significantly during PTH‐RT, whereas plasma calcium and phosphate levels are maintained within the physiologic range. In contrast to the effect of PTH(1–84) treatment in patients with osteoporosis, PTH‐RT in hypoparathyroidism causes a decrease in BMD. This is most likely due to the marked increased bone turnover. Accordingly, PTH‐RT counteracts the state of overmineralized bone and, during long‐term treatment, may cause a more physiologic bone metabolism. © 2011 American Society for Bone and Mineral Research


📜 SIMILAR VOLUMES


Efficacy of selegiline add on therapy to
✍ Afshar Amiri; Ahmad-Ali Noorbala; Ali-Akbar Nejatisafa; Abolfazl Ghoreishi; Moha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract ## Objective It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI‐B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of

Ropinirole is effective in the treatment
✍ Arthur S. Walters; William G. Ondo; Tilman Dreykluft; Ron Grunstein; Daniel Lee; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double‐blind, randomized, 12‐week, multinational study compared the efficacy and safety of ropinirole and placebo in RLS. In total, 267 outpatients with moderate‐to‐

A randomized, double-blind, placebo-cont
✍ Kerri Alexandra Schoedel; Nancy Chen; Annie Hilliard; Linda White; Colin Stott; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB 👁 2 views

## Objective This study aimed to evaluate the abuse potential and cognitive effects of nabiximols (Sativex^®^, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD). ## Methods This was a single‐dose, randomized, double‐bl